$ICPT INTERCEPT PHARMACEUTICALS, INC. Insider Trading Week 15/2014
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in INTERCEPT PHARMACEUTICALS, INC..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in INTERCEPT PHARMACEUTICALS, INC. in week 15/2014.
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Apr 18 2014 | ICPT | INTERCEPT PHARMACE ... | AKKARAJU SRINIVAS | Director | Option Exercise | M | 0.00 | 324 | 0 | 649 | |
Apr 18 2014 | ICPT | INTERCEPT PHARMACE ... | AKKARAJU SRINIVAS | Director | Buy | M | 0.00 | 324 | 0 | 2,267 | 1.9 K to 2.3 K (+16.68 %) |
Apr 17 2014 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Option Exercise | M | 8.67 | 10,000 | 86,667 | 216,628 | |
Apr 17 2014 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Option Exercise | M | 8.67 | 2,866 | 24,839 | 42,999 | |
Apr 17 2014 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Option Exercise | M | 8.67 | 14,332 | 124,211 | 226,628 | |
Apr 17 2014 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Option Exercise | M | 2.89 | 13,111 | 37,876 | 0 | |
Apr 17 2014 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Sell | S | 242.22 | 10,000 | 2,422,166 | 470,174 | 480.2 K to 470.2 K (-2.08 %) |
Apr 17 2014 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Buy | M | 8.67 | 10,000 | 86,667 | 480,174 | 470.2 K to 480.2 K (+2.13 %) |
Apr 17 2014 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Buy | M | 8.67 | 2,866 | 24,839 | 470,174 | 467.3 K to 470.2 K (+0.61 %) |
Apr 17 2014 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Buy | M | 8.67 | 14,332 | 124,211 | 467,308 | 453 K to 467.3 K (+3.16 %) |
Apr 17 2014 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Buy | M | 2.89 | 13,111 | 37,876 | 452,976 | 439.9 K to 453 K (+2.98 %) |
Apr 15 2014 | ICPT | INTERCEPT PHARMACE ... | Regan Daniel Paul | Chief Commercial Of ... | Option Exercise | A | 266.01 | 6,421 | 1,708,050 | 6,421 | |
Apr 15 2014 | ICPT | INTERCEPT PHARMACE ... | Regan Daniel Paul | Chief Commercial Of ... | Option Exercise | A | 266.01 | 1,720 | 457,537 | 1,720 | |
Apr 15 2014 | ICPT | INTERCEPT PHARMACE ... | Regan Daniel Paul | Chief Commercial Of ... | Grant | A | 0.00 | 1,410 | 0 | 1,410 | 0 to 1.4 K |
Apr 15 2014 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Option Exercise | A | 266.01 | 22,931 | 6,099,875 | 22,931 | |
Apr 15 2014 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Option Exercise | A | 266.01 | 5,733 | 1,525,035 | 5,733 | |
Apr 15 2014 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Grant | A | 0.00 | 4,699 | 0 | 439,865 | 435.2 K to 439.9 K (+1.08 %) |
Apr 15 2014 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Option Exercise | M | 21.50 | 1,154 | 24,811 | 8,365 | |
Apr 15 2014 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Option Exercise | A | 266.01 | 6,650 | 1,768,967 | 6,650 | |
Apr 15 2014 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Option Exercise | A | 266.01 | 1,835 | 488,128 | 1,835 | |
Apr 15 2014 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Sell | S | 279.00 | 1,154 | 321,966 | 13,510 | 14.7 K to 13.5 K (-7.87 %) |
Apr 15 2014 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Buy | M | 21.50 | 1,154 | 24,811 | 14,664 | 13.5 K to 14.7 K (+8.54 %) |
Apr 15 2014 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Grant | A | 0.00 | 1,504 | 0 | 13,510 | 12 K to 13.5 K (+12.53 %) |
Apr 15 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Option Exercise | A | 266.01 | 8,255 | 2,195,913 | 8,255 | |
Apr 15 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Option Exercise | A | 266.01 | 1,835 | 488,128 | 1,835 | |
Apr 15 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Grant | A | 0.00 | 1,504 | 0 | 15,183 | 13.7 K to 15.2 K (+10.99 %) |
Apr 15 2014 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Option Exercise | A | 266.01 | 2,293 | 609,961 | 2,293 | |
Apr 15 2014 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Option Exercise | A | 266.01 | 516 | 137,261 | 516 | |
Apr 15 2014 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Grant | A | 0.00 | 423 | 0 | 7,464 | 7 K to 7.5 K (+6.01 %) |